Breaking News, Collaborations & Alliances

Astellas, Cullgen Partner to Advance Targeted Protein Degraders

To combine Cullgen's uSMITE targeted protein degradation platform featuring novel E3 ligands with Astellas' drug discovery capabilities.

Astellas Pharma Inc., a pharmaceutical company, and Cullgen Inc., a clinical-stage biopharmaceutical company, entered into a research collaboration and exclusive option agreement to discover multiple innovative protein degraders.   Under the terms of the agreement, the two companies aim to develop multiple targeted protein degraders by combining Cullgen’s uSMITE targeted protein degradation platform featuring novel E3 ligands with Astellas’ drug discovery capabilities. Cullgen and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters